



Marksans Pharma Ltd.

National Stock Exchange of India Limited
Listing department
Exchange plaza, C-1, Block -G
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051

BSE Limited
Corporate Relation Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

13th August, 2016

Sub: Unaudited Financial Results for the Quarter ended on
30th June, 2016 and Limited Review Report thereon

Dear Sir,

In terms of Clause 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith kindly find Unaudited Financial Results of the Company for the Quarter ended on 30th June, 2016 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held today, i.e. 13th August, 2016 and the Limited Review Report thereon.

You are requested to note the above in your records.

Thanking You.

Yours faithfully,
For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary & Manager-Legal

Enclosed: as above

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com



N. K. MITTAL & ASSOCIATES

CHARTERED ACCOUNTANTS

Tel.: 022-26200030
7208011789
Mob.: 9892640569

Office No. 620, 6th Floor, Pearl Plaza, Opp Andheri Railway Station, Near Mc Donald's, Andheri (West), Mumbai - 400 058.
E-mail : nkmittalandassociates@gmail.com / nkm@nkmittal.com / ca_mittal@rediffmail.com • Website : www.nkmittal.com

N. K. Mittal

B.Com, FCA, LLB, EMBA

LIMITED REVIEW REPORT FOR THE QUARTER ENDED 30.06.2016

Review Report to The Board of Directors, Marksans Pharma Ltd.

We have reviewed the accompanying statement of unaudited financial results of MARKSANS PHARMA LTD for the period ended 30TH June, 2016. This statement is responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. K. MITTAL & ASSOCIATES
Chartered Accountants


N.K. MITTAL
(Proprietor)
M.No.46785
Place: Mumbai
Date: 13.08.2016



MARKSANS PHARMA LIMITED

Registered Office: 11th Floor, Grandeur Veera Desai Extension Road, Oshiwara, Andheri (West), Mumbai-400053 (CIN: L24110MH1992PLC066364)

Telephone No.: 022-4001 2000, Fax No.: 022-4001 2011, E-mail: info@marksanspharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2016

(₹ in Million)

Sr. No.	PARTICULARS	STANDALONE				CONSOLIDATED			
		Quarter ended	Quarter ended	Quarter ended	Previous Year ended	Quarter ended	Quarter ended	Quarter ended	Previous Year ended
		30.06.2016	31.03.2016	30.06.2015	31.03.2016	30.06.2016	31.03.2016	30.06.2015	31.03.2016
		(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)
1	Income from Operations								
a)	Net Sales/ Income from Operations (Net of excise duty)	417.89	694.30	1,023.23	3,581.32	1,867.47	2,102.31	2,101.59	8,933.26
b)	Other Operating Income	-	63.88	22.99	86.87	0.10	64.50	22.99	88.67
	Total Income from operations (net)	417.89	758.18	1,046.22	3,668.19	1,867.57	2,166.81	2,124.58	9,021.93
2	Expenses								
a)	Cost of Material Consumed	195.61	381.31	447.55	1,567.23	913.15	964.02	729.72	3,412.70
b)	Purchase of Stock - in- trade	22.97	30.72	59.65	172.97	349.68	467.79	463.31	1,635.84
c)	Changes in inventories of finished goods , work-in-progress and stock- in- trade	(17.66)	9.12	(17.73)	41.65	(165.00)	15.87	(17.73)	48.40
d)	Employee benefits expense	95.36	89.29	53.13	261.30	382.64	311.09	182.39	1,224.17
e)	Depreciation and amortisation expense	36.70	43.91	26.64	147.48	48.20	83.63	45.24	281.27
f)	Other expenses	68.71	111.49	111.90	499.23	304.42	300.39	242.82	1,249.49
	Total Expenses	401.69	665.84	681.14	2,689.86	1,833.09	2,142.79	1,645.75	7,851.87
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	16.20	92.34	365.08	978.33	34.48	24.02	478.83	1,170.06
4	Other Income	-	-	-	-	-	-	-	-
5	Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)	16.20	92.34	365.08	978.33	34.48	24.02	478.83	1,170.06
6	Finance cost	6.73	8.22	23.81	62.04	12.77	19.69	29.81	101.55
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	9.47	84.12	341.27	916.29	21.71	4.33	449.02	1,068.51
8	Exceptional items	-	-	-	-	-	-	-	-
9	Profit/(Loss) from Ordinary activities before Tax (7-8)	9.47	84.12	341.27	916.29	21.71	4.33	449.02	1,068.51
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	3.00	33.28	102.50	201.43	3.00	43.84	125.66	241.08
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	6.47	50.84	238.77	714.86	18.71	(39.51)	323.36	827.43
12	Extraordinary item (Net of Tax)	-	-	-	-	-	-	-	-
13	Net Profit/ (Loss) for the period (11-12)	6.47	50.84	238.77	714.86	18.71	(39.51)	323.36	827.43



Sr. No.	PARTICULARS	STANDALONE				CONSOLIDATED			
		Quarter ended	Quarter ended	Quarter ended	Previous Year ended	Quarter ended	Quarter ended	Quarter ended	Previous Year ended
		30.06.2016	31.03.2016	30.06.2015	31.03.2016	30.06.2016	31.03.2016	30.06.2015	31.03.2016
		(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)
14	Share of Profit/(Loss) of associates	-	-	-	-	-	-	-	-
15	Minority interest	-	-	-	-	8.47	18.10	8.67	42.31
16	Net Profit/(Loss) after taxes, minority interest and share of associates (13-14-15)	6.47	50.84	238.77	714.86	10.24	(57.61)	314.69	785.12
17	Paid up Equity Share Capital (Face Value ₹1 each)	409.31	409.31	409.31	409.31	409.31	409.31	409.31	409.31
18	Reserve Excluding Revaluation Reserve	-	-	-	3,692.67	-	-	-	4,008.93
19 a)	Earnings Per Share (before extraordinary items- ₹)- Basic	0.02	0.12	0.58	1.75	0.05	(0.10)	0.79	2.02
	Diluted	0.02	0.12	0.58	1.75	0.05	(0.10)	0.79	2.02
	b) Earnings Per Share(after extraordinary items- ₹)- Basic	0.02	0.12	0.58	1.75	0.03	(0.14)	0.77	1.92
	Diluted	0.02	0.12	0.58	1.75	0.03	(0.14)	0.77	1.92

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13.08.2016.
- 2 The Consolidated Financial Statements include Financial Statements of the subsidiaries Marksans Pharma (U.K.) Limited, Marksans Pharma Inc. USA and Nova Pharmaceuticals Australasia Pty Ltd.
- 3 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 4 The figure for the quarter ended March 31, 2016 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2016 and the unaudited published year to date figure upto December 31, 2015 being the date of the end of the third quarter of the financial year.
- 5 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

For MARKSANS PHARMA LIMITED



MARK SALDANHA
Managing Director.

Place: Mumbai.
Date: 13.08.2016
www.marksanspharma.com